An Observational Study Evaluating the Safety of Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients Undergoing Surgery for Non‐Small Cell Lung Cancer
Open Access
- 12 February 2025
- journal article
- Published by Wiley in Thoracic Cancer
- Vol. 16 (3) , e70002
Abstract
Objective: This study was conducted to investigate the safety of neoadjuvant immunotherapy combined with chemotherapy in patients undergoing surgery for resectable stage III non‐small cell lung cancer (NSCLC).Methods: Overall, 68 surgical patients with stage III NSCLC who underwent neoadjuvant therapy at the Thoracic Surgery Department of Beijing Chaoyang Hospital from June 2019 to September 2021 were included, including 19 patients who underwent neoadjuvant chemotherapy combined with immunotherapy and 49 who underwent neoadjuvant chemotherapy alone. Both groups of patients were diagnosed with NSCLC before treatment and had resectable stage III tumors. The surgical duration, blood loss volume, average postoperative hospital length of stay, intensive care unit length of stay, and complication rate were compared between the two groups.Results: The group treated with neoadjuvant chemotherapy combined with immunotherapy demonstrated higher values than the group treated with chemotherapy alone for surgical duration, blood loss volume, and rate of conversion to thoracotomy; however, the differences were not statistically significant. The incidence of postoperative complications in the group treated with neoadjuvant immunotherapy combined with chemotherapy was significantly higher than that of the group treated with neoadjuvant chemotherapy alone (p = 0.02).Conclusion: Neoadjuvant immunotherapy combined with chemotherapy was safe and effective and did not increase the difficulty of surgery for NSCLC; however, it was associated with a higher incidence of complications than neoadjuvant chemotherapy alone (p < 0.05).Keywords
This publication has 17 references indexed in Scilit:
- Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non–small cell lung cancerThe Journal of Thoracic and Cardiovascular Surgery, 2019
- The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid MalignanciesAnnals of Surgical Oncology, 2018
- Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical EvidenceClinical Cancer Research, 2014
- Neoadjuvant chemo-immunotherapy modifies CD4+CD25+ regulatory T cells (Treg) in non-small cell lung cancer (NSCLC) patientsLung Cancer, 2014
- The Effects of Neoadjuvant Chemotherapy on Pulmonary Structures: A Quantitative AnalysisThe Thoracic and Cardiovascular Surgeon, 2011
- Treatment of ovarian cancer cell lines with 5-aza-2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded moleculesCancer Immunology, Immunotherapy, 2008
- Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative GroupJournal of Clinical Oncology, 2008
- Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung CancerJournal of Thoracic Oncology, 2008
- Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune ActivityClinical Cancer Research, 2005
- Treatment of colon and breast carcinoma cells with 5‐fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA‐A(*)02.01 restricted, CEA‐peptide‐specific cytotoxic T cells in vitroInternational Journal of Cancer, 2003